Institutional members access full text with Ovid®

Share this article on:

Fourteen Day In Vivo Testing of a Compliant Thoracic Artificial Lung

Skoog, David J.*; Pohlmann, Joshua R.; Demos, David S.†‡; Scipione, Christopher N.; Iyengar, Amit*; Schewe, Rebecca E.*; Suhaib, Ahmed B.*; Koch, Kelly L.; Cook, Keith E.*†

doi: 10.1097/MAT.0000000000000627

The compliant thoracic artificial lung (cTAL) has been studied in acute in vivo and in vitro experiments. The cTAL’s long-term function and potential use as a bridge to lung transplantation are assessed presently. The cTAL without anticoagulant coatings was attached to sheep (n = 5) via the pulmonary artery and left atrium for 14 days. Systemic heparin anticoagulation was used. Compliant thoracic artificial lung resistance, cTAL gas exchange, hematologic parameters, and organ function were recorded. Two sheep were euthanized for nondevice-related issues. The cTAL’s resistance averaged 1.04 ± 0.05 mmHg/(L/min) with no statistically significant increases. The cTAL transferred 180 ± 8 ml/min of oxygen with 3.18 ± 0.05 L/min of blood flow. Except for transient surgical effects, organ function markers were largely unchanged. Necropsies revealed pulmonary edema and atelectasis but no other derangements. Hemoglobin levels dropped with device attachment but remained steady at 9.0 ± 0.1 g/dl thereafter. In a 14 day experiment, the cTAL without anticoagulant coatings exhibited minimal clot formation. Sheep physiology was largely unchanged except for device attachment-related hemodilution. This suggests that patients treated with the cTAL should not require multiple blood transfusions. Once tested with anticoagulant coatings and plasma resistant gas exchange fiber, the cTAL could serve as a bridge to transplantation.

From the *Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan; Department of Surgery, University of Michigan, Ann Arbor, Michigan; and Department of General Surgery, Henry Ford Health System, Detroit, Michigan.

Submitted for consideration November 2016; accepted for publication in revised form June 2017.

This work was supported with a federal R01 grant, National Institutes of Health/National Heart, Lung, and Blood Institute R01 HL089043.

Disclosure: Dr. Cook and Dr. Skoog are equity owners of Advanced Respiratory Technologies LLC. Advanced Respiratory Technologies LLC was founded after this work was completed and has no rights in regard to its publication.

Correspondence: Keith E. Cook, Associate Professor of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Scott Hall 4th Floor, Pittsburgh, PA 15213. Email:

Copyright © 2017 by the American Society for Artificial Internal Organs